Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 5,559 Shares of Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 5,559 shares of the business’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $4.10, for a total value of $22,791.90. Following the sale, the insider directly owned 550,000 shares in the company, valued at $2,255,000. This trade represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Monday, February 2nd, Chidozie Ugwumba sold 3,800 shares of Clene stock. The stock was sold at an average price of $4.04, for a total value of $15,352.00.
• On Friday, January 30th, Chidozie Ugwumba sold 5,686 shares of Clene stock. The stock was sold at an average price of $4.13, for a total value of $23,483.18.
• On Thursday, January 29th, Chidozie Ugwumba sold 15,284 shares of Clene stock. The shares were sold at an average price of $4.32, for a total transaction of $66,026.88.
• On Wednesday, January 28th, Chidozie Ugwumba sold 8,717 shares of Clene stock. The stock was sold at an average price of $4.91, for a total transaction of $42,800.47.
• On Tuesday, January 27th, Chidozie Ugwumba sold 4,139 shares of Clene stock. The shares were sold at an average price of $5.08, for a total value of $21,026.12.
• On Monday, January 26th, Chidozie Ugwumba sold 6,418 shares of Clene stock. The shares were sold at an average price of $5.02, for a total transaction of $32,218.36.
• On Friday, January 23rd, Chidozie Ugwumba sold 5,556 shares of Clene stock. The shares were sold at an average price of $5.27, for a total value of $29,280.12.
• On Thursday, January 22nd, Chidozie Ugwumba sold 12,665 shares of Clene stock. The stock was sold at an average price of $5.32, for a total value of $67,377.80.
• On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The stock was sold at an average price of $5.05, for a total transaction of $61,200.95.
• On Tuesday, January 20th, Chidozie Ugwumba sold 12,432 shares of Clene stock. The shares were sold at an average price of $4.80, for a total transaction of $59,673.60.

Clene Stock Performance

NASDAQ:CLNN traded up $0.15 during mid-day trading on Friday, hitting $4.07. The company had a trading volume of 17,007 shares, compared to its average volume of 111,336. The firm has a market cap of $44.16 million, a P/E ratio of -1.20 and a beta of 0.81. The business’s fifty day moving average is $5.89 and its two-hundred day moving average is $6.53. Clene Inc. has a fifty-two week low of $2.28 and a fifty-two week high of $13.50.

Clene (NASDAQ:CLNN) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. Equities analysts forecast that Clene Inc. will post -5.19 earnings per share for the current year.

Hedge Funds Weigh In On Clene

Several institutional investors and hedge funds have recently added to or reduced their stakes in CLNN. Scoggin Management LP grew its position in Clene by 75.1% during the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after purchasing an additional 107,250 shares during the last quarter. Lunt Capital Management Inc. lifted its stake in shares of Clene by 2.5% in the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock worth $315,000 after purchasing an additional 1,250 shares during the period. Jones Financial Companies Lllp purchased a new stake in shares of Clene in the 3rd quarter worth $29,000. Finally, Jane Street Group LLC bought a new position in shares of Clene in the second quarter worth about $47,000. Hedge funds and other institutional investors own 23.28% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on CLNN shares. Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a research report on Friday, January 9th. UBS Group reissued a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. D. Boral Capital reaffirmed a “buy” rating and set a $23.00 price target on shares of Clene in a research report on Friday, January 9th. Finally, Benchmark reiterated a “buy” rating on shares of Clene in a research report on Thursday, December 4th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Clene currently has an average rating of “Moderate Buy” and a consensus price target of $32.60.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).